Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Someone pointed out SVA—Sernova Corp

<< Previous

Bullboard Posts

Next >>

Comment by auricgoldon Dec 30, 2020 3:42pm

218 Views

Post# 32199318

RE:Someone pointed out SVA—Sernova Corp

its a no brainer even with a market cap of 50 million.

Pimpovish wrote: SVA--$142 million marketcap.
This is a lesser evolved company and its running hot. They have currently enrolled 5 patients for clinical trials. Their tech is based on cellular transplantation.
HEM--post rollback, post financing has a marketcap of $39 million. 10 years of data based on clinicals with a high number of patients and 91 patents around cultured cellular growth and transplantation.
The majority of investors in this stock are longer term and not looking to lock in short term gains.
To be fair, theres nothing wrong in taking profits but like a lot of investors on this one, I'm looking for a homerun.